Somavert, Mesnex Join Medicare Rx Demo
This article was originally published in The Pink Sheet Daily
Executive Summary
The Pfizer and Baxter products are part of an updated list of drugs that will be reimbursed under a Part B demonstration for oral substitutes of injectable drugs.
You may also be interested in...
Medicare Part B Oral Chemotherapy Demo To Cover Tamoxifen and Thalidomide
In announcing the start of the demonstration project, CMS departs from earlier demo criteria by saying that tamoxifen qualifies as a “replacement” drug and thalidomide is covered because it has a pending supplemental NDA for an indication qualifying it for the project.
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Deal Watch: Sanofi, Boehringer Swap Side Businesses
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.